GENEVA - 
Buying illegal tobacco products is in danger of becoming normalized, with 43% of adult smokers surveyed comfortable buying cigarettes, even if they know they are produced or sold illegally.
Governments’ inability to collect tax revenue due to the illegal tobacco trade is a significant issue for 88% of respondents.
Around half of the respondents cite illegal tobacco trade as being a threat to their country.
61% of respondents do not believe that the sale of illegal tobacco is a victimless crime.
 

(BUSINESS WIRE) -- The new study Fighting the Dark Underworld: How the illegal trade in tobacco threatens to overwhelm us, by Intrinsic Insight and commissioned by JTI, sheds new light on the pervasiveness of organized crime within global society, focusing on four countries with high levels of illicit tobacco trade: Canada, France, Philippines, and the United Kingdom.

The report, released today, examines the “dark ... Read more »

OSAKA, Japan & CAMBRIDGE, Mass. - Monday, 24. June 2024 Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161 Mezagitamab Had a Favorable Safety Profile, with No New Safety Signals1 Takeda Plans to Initiate Global Phase 3 Trial of Mezagitamab in ITP in the Second Half of FY2024 (BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of ... Read more »

OSAKA, Japan & CAMBRIDGE, Mass. - Monday, 24. June 2024 AETOSWire 

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1
CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Secondary Infections and Serious Consequences, Including Loss of Transplanted Organ and Failure of Graft2,3
 

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1

“We are pleased by the approval of LIVTENCITY in Japan, which will provide the transplant community with a ne ... Read more »